tirzepatide and breast cancer 🚨Scientists found an FDA-approved druge that shrinks tumors! In an unexpected promising discovery, researchers have found that tirzepatide, a drug approved for diabetes and weight loss under the names Cancer: ENDO 2025 | Tirzepatide

While the effects of GIP receptor antagonism on these outcomes remain unknow, GIPR knockout mice have been shown to exhibit impaired learning and memory, as well as reduced synaptic plasticity (111)

Remember that the starting dose (typically 2.5 mg) is intentionally low to minimize side effects, and your body will gradually adapt as doses are titrated upward every four weeks based on glycemic response and tolerability

Im Scott Melamed, President and CEO of ProMD Health, where weve helped thousands of patients achieve natural-looking results with advanced regenerative treatments including PRP under eyes before and after changes

Most importantly, doses below 2.5 mg weekly have not been studied for efficacy in weight management, meaning there is no evidence that microdosing produces clinically meaningful weight loss

The final report is ultimately the responsibility of the study director, who prepares and approves the report

For people living with high cortisol levels, which can occur in conditions like Cushings syndrome, understanding how semaglutide interacts with cortisol is crucial